Cerebrolysin (EVER Neuro Pharma GmbH, Austria) is a peptidergic drug indicated for clinical use in stroke, traumatic brain injury and dementia. The therapeutic effect of Cerebrolysin is thought to ensure from its neurotrophic activity, which shares some properties with naturally occurring neurotrophic factors. However, the exact mechanism of action of Cerebrolysin is yet to be fully deciphered. This study aimed to investigate the neuroprotective effect of Cerebrolysin in a widely used in vitro model of hypoxia-induced neuronal cytotoxicity, namely cobalt chloride (CoCl 2 )-treatment of PC12 cells. CoCl 2 -cytotoxicity was indicated by a reduced cell-diameter, cell shrinkage, increased pro-apoptotic Caspase-activities and a decreased metabolic activity. Cerebrolysin maintained the cell-diameter of CoCl 2 -treated naïve PC12 cells, decreased the activation of Caspase 3/7 in CoCl 2 -stressed naïve PC12 cells and restored the cells' metabolic activity in CoCl 2 -impaired naïve and differentiated PC12 cells. Cerebrolysin treatment also decreased the levels of superoxide observed after exposure to CoCl 2 . Investigating the mechanism of action, we could demonstrate that Cerebrolysin application to CoCl 2 -stressed PC12 cells increased the phosphorylation of GSK3␤, resulting in the inhibition of GSK3␤. This might become clinically relevant for Alzheimer's disease, since GSK3␤ activity has been linked to the production of amyloid beta. Taken together, Cerebrolysin was found to have neuroprotective effects in CoCl 2 -induced cytotoxicity in PC12 cells.
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Introduction
A central hallmark of neurodegenerative diseases and acute CNS lesions is neuronal cell death, which constitutes the prime cause of associated functional deficits such as cognitive and motor disabilities. In consequence, strategies aiming to protect neurons from cell death have been under development over the past decades. The identification of neurotrophic factors such as nerve growth factor (NGF, Cohen, 1960 ) and brain-derived neurotrophic factor (BDNF, Lindsay et al., 1985) triggered the search for druggable brain-derived neurotrophic activities (Longo and Massa, 2013) . Cerebrolysin is produced by a standardized biochemical breakdown of brain lysates and consists of low molecular weight peptides and amino acids (EBEWENeuroPharmaGmbH, 2009) . The resulting drug displays neurotrophic activity (Mallory et al., 1999; Masliah and Diez-Tejedor, 2012) , protects primary neurons from glutamate-induced excitotoxicity (Hutter-Paier et al., 1996) , displays neuroprotective activity in animal models of neurodegeneration (Francis-Turner et al., 1996; Francis-Turner and Valouskova, 1996; Valouskova and Francis-Turmer, 1996; Masliah et al., 1999; Veinbergs et al., 2000) or ischemic and traumatic CNS lesions (Zhang et al., 2013a,b) and modulates endogenous neurotrophin levels (Ubhi et al., 2013) . Furthermore, Cerebrolysin is used in human to treat dementia, stroke and traumatic brain injuries. In this respect, Cerebrolysin administration was reported http://dx.doi.org/10.1016/j.ijdevneu.2014.07.005 0736-5748/© 2014 ISDN. Published by Elsevier Ltd. All rights reserved.
